Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials

Journal of Urology

Volumn 168, Issue 5, 2002, Pages 1964-1970

  Sylvester, Richard J ^a   Van der Meijden, Adrian P M ^a   Lamm, Donald L ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Bladder neoplasms; Disease progression; Meta analysis

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OUTCOMES RESEARCH; PAPILLOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION;

EID: 0036837453     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64273-5     Document Type: Article

References (34)

1. Lum, B. L. and Torti, F. M.: Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst, 83: 682, 1991
2. Pawinski, A., Sylvester, R., Kurth, K. H., Bouffioux, C., van der Meijden, A., Parmar, M. K. B. et al: A combined analysis of European Organization for research and treatment of cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol, 156: 1934, 1996
3. Lamm, D. L., Riggs, D. R., Traynelis, C. L. and Nseyo, U. O.: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol, 153: 1444, 1995
4. Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K. et al: A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int, 88: 209, 2001
5. Cookson, M. S., Herr, H. W., Zhang, Z.-F., Soloway, S., Sogani, P. C. and Fair, W. R.: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158: 62, 1997
6. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D. and Garbeglio, A.: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol, 146: 32, 1991
7. Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F. et al: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol, 5: 441, 1987
8. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol, 163: 1124, 2000
9. Palou, J., Laguna, P., Millán-Rodríguez, F., Hall, R. R., Salvador-Bayarri, J. and Vicente-Rodríguez, J.: Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol, 165: 1488, 2001
10. Rintala, E., Jauhiainen, K., Kaasinen, E., Nurmi, M., Alfthan, O. and Finnbladder Group: Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol, 156: 56, 1996
11. Rintala, E., Jauhiainen, K., Rajala, P., Ruutu, M., Kaasinen, E., Alfthan, O. et al: Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol, 154: 2050, 1995
12. Witjes, J. A., Caris, C. T. M., Mungan, N. A., Debruyne, F. M. J. and Witjes, W. P. J.: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol, 160: 1668, 1998
13. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Crissman, J. D., Lowe, B. A., Smith, J. A., Jr. et al: Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol, 1: 119, 1995
14. Malmström, P.-U., Wijkström, H., Lundholm, C., Wester, K., Busch, C., Norlén, B. J. et al: 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder cancer. J Urol, 161: 1124, 1999
15. Nogueira March, J. L., Solsona, E., Unda, M., Ojea, A., Rodriguez-Molina, A., Fernandez, J. et al: A multicenter and randomised prospective study comparing three intravesical therapies, two with bacillus Calmette-Guerin immunotherapy and one with mitomycin C chemotherapy in medium and low risk superficial bladder cancer. Eur Urol, suppl., 39: 32, abstract 119, 2001
16. Rintala, E., Jauhiainen, K., Alfthan, O., Hansson, E., Juusela, H., Kanerva, K. et al: Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur Urol, 20: 19, 1991
17. Vegt, P. D. J., Witjes, J. A., Witjes, W. P. J., Doesburg, W. H., Debruyne, F. M. J. and van der Meijden, A. P. M.: A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol, 153: 929, 1995
18. Witjes, J. A., van der Meijden, A. P., Collettee, L., Sylvester, R., Debruyne, F. M., van Aubel, A. and Witjes, W. P.: Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacillus Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology, 52: 403, 1998
19. Martínez-Piñeiro, J. A., Jiménez León, J., Martínez-Piñeiro, L., Jr., Fiter, L., Mosteiro, J. A., Navarro, J. et al: Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol, 143: 502, 1990
20. De Reijke, T. M., Kurth, K. H., Hall, R. R., Brausi, M., Morjaria, U., Sylvester, R. et al: First results of a phase III study comparing BCG and epirubicin in TIS of the bladder: an EORTC GU Group study. Eur Urol, suppl., 39: 32, abstract 118, 2001
21. Melekos, M. D., Chionis, H. S., Paranychianakis, G. S. and Dauaher, H. H.: Intravesical 4′-epi-doxorubin (epirubicin) versus bacillus Calmette-Guerin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer, 72: 1749, 1993
22. van der Meijden, A. P. M., Brausi, M., Zambon, V., Kirkels, W., de Balincourt, C., Sylvester, R. et al: Intravesical instillation of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette- Guerin plus isoniazid for intermediate and high risk TA, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol, 166: 476, 2001
23. Brosman, S.: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol, 128: 27, 1982
24. Witjes, W. P., Konig, M., Boeminghaus, F. P., Hall, R. R., Schulman, C. C., Zurlo, M. et al: Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol, 36: 576, 1999
25. Jimenez-Cruz, J. F., Vera-Donoso, C. D., Leiva, O., Pamplona, M., Rioja-Sanz, L. A., Martinez-Lasierra, M. et al: Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology, 50: 529, 1997
26. Kalble, T., Beer, M., Mendoza, E., Ikinger, U., Link, M., Reichert, H. E. et al: [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study.] Urologe A, 33: 133, 1994
27. Kalble, T., Mohring, K., Ikinger, U., Riedasch, G. and Staehler, G.: [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study.] Urologe A, 30: 118, 1991
28. Ibrahiem, E.-H. I., Ghoneim, M. A., Nigam, V., Brailovsky, C. and Elhilali, M. M.: Prophylactic maltose tetrapalmitate and bacillus Calmette-Guerin immunotherapy of recurrent superficial bladder tumors: preliminary report. J Urol, 140: 498, 1988
29. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B. et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med, 325: 1205, 1991
30. Herr, H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., Jr. et al: Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol, 13: 1404, 1995
31. Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., Sylvester, R. et al: A prospective European Organization for Research and Treatment of Cancer Genito- urinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol, 149: 749, 1993
32. van der Meijden, A. D. P.: Bacillus Calmette-Guerin (BCG) for transitional cell carcinoma of the bladder. In: Clinical Management of Bladder Cancer. Edited by R. R. Hall. New York: Oxford University Press, chapt. 5, pp. 125-147, 1999
33. Lamm, D. L., Stogdill, V. D., Stogdill, B. J. and Crispen, R. G.: Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol, 135: 272, 1986
34. Lamm, D. L., van der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W. et al: Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol, 147: 596, 1992